Ironwood Pharmaceuticals, Inc. Class A
(NASDAQ : IRWD)

( )
IRWD PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SHPGShire PLC Sponsored ADR
-3.02%172.750.4%$312.80m
AMRNAmarin Corporation Plc Sponsored ADR
-6.00%16.912.0%$244.81m
JAZZJazz Pharmaceuticals Plc
-1.62%141.172.2%$120.91m
PRGOPerrigo Co. Plc
-4.30%59.936.8%$105.96m
GWPHGW Pharmaceuticals PLC Sponsored ADR
1.73%124.846.3%$61.48m
MNKMallinckrodt Plc
-3.62%20.7521.1%$55.15m
ENDPEndo International Plc
-0.26%11.578.9%$50.42m
ICLRICON Plc
-1.64%139.634.1%$44.84m
HZNPHorizon Pharma plc
-2.04%19.657.4%$42.45m
UTHRUnited Therapeutics Corporation
-2.95%109.4414.4%$40.43m
SAGESAGE Therapeutics, Inc.
-3.02%102.689.6%$39.65m
ICPTIntercept Pharmaceuticals, Inc.
-4.26%102.2618.6%$38.77m
CTLTCatalent Inc
-2.68%36.312.4%$37.78m
PTLAPortola Pharmaceuticals, Inc.
0.73%20.687.7%$32.06m
ZGNXZogenix, Inc.
-2.43%42.5510.0%$25.36m

Company Profile

Ironwood Pharmaceuticals, Inc. operates as commercial biotechnology company, which discovers, develops and commercializes differentiated medicines that improve patient's lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook, Jr. and Gina Bornino Miller on January 5, 1998 and is headquartered in Cambridge, MA.